Black Di­a­mond turns down an open stretch of R&D high­way, head­ed to a show­down with onco­genes

As one of the lead sci­en­tists in­volved in the de­vel­op­ment of Tarce­va, David Ep­stein had plen­ty of op­por­tu­ni­ty to con­sid­er the many ways in which can­cer can evade a drug and kill pa­tients.

For the last 4 years, Ep­stein has been qui­et­ly work­ing away at the prob­lem, and he’s tak­en a turn down a stretch of R&D high­way which he be­lieves can lead to a full pipeline of new can­cer drugs that can broach that is­sue for par­tic­u­lar sub­sets of pa­tients. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER